UNSPSC 51183700: Antidiabetic and hyperglycemic thiazolidinediones

This classification denotes substances that chemically consist of thiazoles with two keto oxygens, substances thus called thiazoli-di-nediones, that help regulate blood glucose levels, thus the term ANTIDIABETIC AND HYPERGLYCEMIC THIAZOLIDINEDIONES.

UNSPSC 51183700 Antidiabetic and hyperglycemic thiazolidinediones is a Class code that covers pharmaceutical products supplied through multistate cooperative purchasing mechanisms to state and local government health systems, correctional facilities, and other public agencies. State and local buyers under this code procure generic and branded antidiabetic medications — including thiazolidinedione drugs and related hyperglycemic treatments — through cooperative agreements that establish pricing, wholesaler relationships, and compliance requirements with the FDA, current Good Manufacturing Practices (cGMP), and the Drug Supply Chain Security Act (DSCSA). Issuing bodies include state purchasing offices administering multistate cooperative alliances, state health departments, county health systems, and city and county correctional and detention facilities. The primary recent activity is driven by multistate cooperative purchasing vehicles, which consolidate demand across multiple jurisdictions and negotiate volume discounts with pharmaceutical manufacturers and authorized wholesalers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including antidiabetic medications, for distribution across Minnesota, Oregon, and other participating state and local facilities. Vendors must secure relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencara, Cardinal Health, and Morris & Dickson Co., LLC), maintain comprehensive insurance coverage including $5 million in commercial general liability per occurrence, and submit detailed product information including NDC codes, SKUs, UPCs, strength, dosage form, and manufacturing locations in CSV format through the ePro procurement system by the March 26, 2026 deadline. Pricing evaluation weights price competitiveness at 75 percent, with additional evaluation criteria covering fixed pricing, EDI capability, administrative fee compliance, and format requirements. Awarded vendors will supply products effective July 1, 2026, under a two-year initial contract term with optional MMCAP extensions.